Bone and Bones – Talk Bio

Actionable Insights Powered by AI

Biohaven’s Taldefgrobep Alfa Shifts Focus to Obesity After Missing Primary Endpoint in Spinal Muscular Atrophy Phase 3 Trial

5 months ago talkbio0Tagged Alfa, Body Composition, Bone and Bones, density, GDF8 protein, human, Inhibitor, lean, Obesity, Phase 3 trial, Spinal Muscular Atrophy

Biohaven, taldefgrobep alfa, spinal muscular atrophy (SMA), obesity, myostatin inhibitor, phase 3 trial, body composition, lean muscle mass, bone density.